We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Department of Pharmacology, JES’s SND College of Pharmacy, Babhulgaon, Dist. Nashik, India
Toxoplasmosis is a widespread zoonotic infection caused by the protozoan parasite Toxoplasma gondii, which primarily infects cats and can be transmitted to humans through various routes. The infection is prevalent worldwide, with varying degrees of severity depending on the host?s immune status. While many cases are asymptomatic, individuals with compromised immune systems, such as those with HIV/AIDS, organ transplant recipients, or pregnant women, are at a higher risk for severe complications. These complications can include toxoplasmic encephalitis (a life-threatening inflammation of the brain), ocular toxoplasmosis (retinal inflammation leading to vision loss), and congenital toxoplasmosis, which can result in miscarriage, stillbirth, or severe neurological disorders in newborns. The clinical manifestations of toxoplasmosis range from mild, flu-like symptoms in immunocompetent individuals to more severe, life-threatening conditions in those with weakened immunity. Diagnosis relies on a combination of serological tests, such as the detection of IgM and IgG antibodies, as well as molecular diagnostics (e.g., PCR) for detecting T. gondii DNA, and imaging techniques (e.g., CT or MRI) to identify characteristic lesions in the brain. For severe cases, a histopathological examination of tissue samples may be required. Treatment for toxoplasmosis is primarily based on a combination of pyrimethamine and sulfadiazine, which inhibit the parasite?s ability to replicate, although alternative therapies such as clindamycin or spiramycin can be used depending on the patient?s condition and response to treatment. Immunocompromised patients, including HIV/AIDS patients, may require long-term maintenance therapy to prevent reactivation of the infection. Prevention strategies are essential in reducing the transmission of T. gondii. Control measures in the management of pet cats and prevention of stray animals are also critical in limiting the environmental sources of infection. In conclusion, toxoplasmosis remains a significant public health issue with the potential for severe health consequences, especially for immunocompromised individuals and pregnant women. Early diagnosis, effective treatment, and preventive measures are essential for controlling the spread of this zoonotic disease and mitigating its impact on vulnerable populations. Ongoing research into the molecular biology, epidemiology, and management of toxoplasmosis is crucial to develop more effective strategies for prevention and treatment.
Zoonotic diseases, also known as zoonoses, are infectious diseases that are transmitted between animals and humans. These diseases are caused by a variety of pathogens, including bacteria, viruses, parasites, and fungi, which can be transmitted directly or indirectly from animals to humans. Zoonoses represent a significant threat to global public health as they account for more than 60% of all human infectious diseases, with over 70% of emerging infectious diseases having an animal origin (1). Examples of zoonotic diseases include rabies, avian influenza, Ebola, and Toxoplasmosis. Zoonoses not only pose direct health risks but also contribute to economic burdens on health systems and agricultural sectors due to their impact on livestock and wildlife populations (2). Their transmission is influenced by environmental factors, human behavior, and the close interactions between humans and animals, particularly in urbanization, global trade, and climate change (3). Toxoplasmosis, caused by the protozoan Toxoplasma gondii, is one of the most common zoonotic infections worldwide, with significant public health implications. This disease is typically associated with domestic cats, which are the definitive hosts of the parasite, but humans and other animals can also serve as intermediate hosts. The significance of Toxoplasmosis lies in its ability to cause a wide spectrum of clinical manifestations, ranging from asymptomatic infections to severe outcomes such as encephalitis, ocular toxoplasmosis, and congenital toxoplasmosis, which can lead to neurological and developmental issues in newborns (4). It is a particularly serious concern for immunocompromised individuals, such as those with HIV/AIDS or organ transplant recipients, who are at increased risk for developing more severe forms of the disease (5). Furthermore, the potential for congenital transmission during pregnancy highlights the importance of early detection and management of the disease in pregnant women, as it can result in miscarriage, stillbirth, or lifelong disabilities in the child (6). Toxoplasmosis has a global distribution, with prevalence rates varying depending on geographic location, socio-economic conditions, and cultural practices. Studies suggest that approximately one-third of the global population has been exposed to Toxoplasma gondii at some point in their lives (7). The disease is more common in areas where foodborne transmission is prevalent, such as regions where undercooked meat is a part of the diet, or where there is poor sanitation and close contact with animals, particularly cats (8). For example, the prevalence of T. gondii antibodies is higher in countries in Latin America, Eastern Europe, and parts of Africa, while lower in parts of Asia and Scandinavia (9). In the United States, it is estimated that around 11% of the population is infected, but most cases are asymptomatic or mild (10). The distribution of the disease can be influenced by multiple factors, including the presence of domestic cats, agricultural practices, and food safety standards (11). Additionally, the disease has a substantial impact on public health due to its chronic nature and the associated healthcare costs related to treating severe cases, especially in immunocompromised individuals and pregnant women (12)
Kiran Kulkarni*, Pooja Rasal, Shalvi Pawar, Suyash Pawar, Zoonotic Diseases: A Comprehensive Review of Toxoplasmosis and its Impact on Public Health, Int. J. Sci. R. Tech., 2025, 2 (11), 607-615. https://doi.org/10.5281/zenodo.17668205
10.5281/zenodo.17668205